Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.46 |
| ▸ | MDM4 | O15151 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14265315 | 1.00 | CASP3 (0.52) | CASP3KMT2AMDM2MDM4TP53 | |
| SCHEMBL16061957 | 0.93 | KMT2A (0.50) | CASP3KMT2AMDM2MDM4TP53 | |
| SCHEMBL16060727 | 0.92 | CASP3 (0.50) | CASP3KMT2AMDM2MDM4TP53 | |
| SCHEMBL25206792 | 0.92 | CASP3 (0.50) | CASP3KMT2AMDM2MDM4TP53 | |
| SCHEMBL25268084 | 0.92 | CASP3 (0.50) | CASP3KMT2AMDM2MDM4TP53 | |
| SCHEMBL119715 | 0.91 | CASP3 (0.55) | CASP3KMT2AMDM2MDM4TP53 | |
| SCHEMBL14265316 | 0.91 | CASP3 (0.55) | CASP3KMT2AMDM2MDM4TP53 | |
| SCHEMBL29402145 | 0.91 | CASP3 (0.55) | CASP3KMT2AMDM2MDM4TP53 | |
| SCHEMBL29398965 | 0.90 | CASP3 (0.45) | CASP3KMT2AMDM2MDM4TP53 | |
| SCHEMBL6609333 | 0.90 | CASP3 (0.45) | CASP3KMT2AMDM2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332300-A1 | HER2 TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2025-10-30 | — | — | US | disclosed |
| CN-115925790-A | Methods for synthesizing alpha 4 beta 7 peptide antagonists | 领导医疗有限公司 | 2023-04-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332300-A1 | HER2 TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | ERBB2, EGFR, ERBB3 | CASP3 1904/4885KMT2A 3524/4885MDM2 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.